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Abstract
Background: The present study aimed to develop an Analytic Network Process (ANP) model to assist policymakers
in identifying and prioritizing allocation indicators, which are being used or should be used to distribute drugs in
short supply among different provinces.
Methods: The model encompasses the interactions between various indicators and efficiency, equity, and
effectiveness paradigms. Accordingly, a set of clusters and elements, which were associated with the allocation of
drugs in short supply in Iran’s pharmaceutical system, were detected to develop the model and were then
compared in pairs in terms of a specified factor to show the priorities.
Results: Equity had the highest priority (0.459) following by Efficiency (0.37), and Effectiveness (0.171). The 4 most
important allocation indicator were “number of prescriptions” (0.26) and “total bed occupancy rate” (0.19) related to equity,
“total population” (0.21) in efficiency and “the burden of rare and incurable disease” (0.07) in effectiveness paradigm.
Conclusions: The capability to overcome inefficient resource allocation patterns caused by both oversupply and
undersupply derived from historic resource allocation may be highly limited in the absence of the need indicators. The
quality of the decision is related to a careful balancing act of the three paradigms which represents roughly the triple aim
of public healthcare systems: clinical improvement (effectiveness), population health improvement (equity and access), and
reducing cost (economic aspects -efficiency).
Keywords: Equity, Efficiency, Effectiveness, Resource allocation, Scarce drugs allocation, Need-based resource allocation,
Analytic network process
Background
Drug shortage occurs because of a failure to follow prede-
termined supply programs [1]. At the time of shortage, the
health systems’ immediate action is essential to prevent dis-
ruptions in patient care [2]; hence, activities associated with
drug shortage management need to be of priority, com-
pared to other tasks, to ensure the supply of an essential
medication or its alternative [2, 3]. A number of studies
point out that drug shortage has been increasing over the
recent decades [3, 4], posing the health care systems an on-
going challenge [2]. Furthermore, there is no unified theory
or framework defined to manage such issues [2, 5].
Currently, Iran’s pharmaceutical system is suffering
from regular short supply of some medications, especially
those used to treat non-communicable diseases [6], in the
market, and the inefficient structure of the current supply
chain has also aggravated the problem [7, 8]. Although
there has been a significant increase in the number of in-
dividuals having access to basic pharmaceuticals over the
past decade, the lack of access to sustainable resources is
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: peiravianfarzad@gmail.com
3Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid
Beheshti University of MedicalSciences, Tehran, Iran
Full list of author information is available at the end of the article
Zarei et al. BMC Health Services Research          (2020) 20:626 
https://doi.org/10.1186/s12913-020-05477-y
still a problem [9]. However, increasing the accessibility of
medications in short supply is not possible unless a reli-
able drug supply system, which can ensure an adequate
distribution of resources, is operating [10].
A review of the experiences of other countries reveals
a need to shift the discussion from questioning to imple-
mentation of best practices in this field [11]. Employing
a number of mechanisms, categorized in the form of
supply and demand side mechanisms, to allocate rare
healthcare resources is possible [12]. There are different
indicators in each side, and a simple/ a single indicator
as well as composite indicators has been utilized by dif-
ferent countries to weigh the population of the district.
In several countries concerned with the concept of needs
in the allocation of their resources, composite indicators
of socioeconomic conditions, including deprivation and
asset indicators, have been employed. Demographic and
socioeconomic status, including population size, age,
gender, and health status are also commonly applied in
developing countries [13–16].
Challenges of Iran’s pharmaceutical system regarding
drugs in short supply
In Iran, Iran Food and Drug Administration (IFDA) is in
charge of supervising all issues posed in the pharmaceut-
ical sector. Ensuring public access to effective and safe
medications at affordable prices, specifically those stipu-
lated in the Islamic Republic of Iran’s 20-year national
vision document and Iran National Drug Policy (INDP)
[17, 18], is one of the primary goals of IFDA.
Since drug shortage is inevitable, policy makers should
be provided with dependable and appropriate informa-
tion to offer successful and efficient management for the
problem [2, 5, 19]. According to some practical evidence,
IFDA implements a proactive inventory program to col-
lection thorough information about drugs in short [9].
IFDA’s information center of medicine, universities of
medical sciences, and some referral pharmacies across
the country gather the required information. Despite
collecting data via routine market monitoring across the
country, the warning system cannot be considered as a
comprehensive system and should be upgraded to an ad-
vanced structure through enhancing collaboration
among stakeholders and improving IFDA’s capability to
exert control over the pharmaceutical market [7]. An-
other responsibility of IFDA is to ensure that a definite
distribution policy is in place during shortages. Evidence
has revealed that provinces are prioritized when drug
shortages occur in the country [1]; therefore, this con-
trolled allocation program can be regarded as a type of
implicit healthcare rationing. Like other countries, it is
proposed in Iran that clear policies governing the alloca-
tion of scarce resources help the healthcare system to al-
locate this valuable resource successfully [20], and that
some considerations are needed to determine factors
leading to variations among the populations of each prov-
ince in order to perform rationing effectively [21, 22].
Need-based resource allocation
According to the World Health Report 2000, the goals of
health systems are good health for citizens, accountability
for what the population expects, and equitable means of
funding operations. Accordingly, a health care system is
mostly evaluated by its progress towards the goals.
Duckett (2008) suggested a two dimensional method
to evaluate the health care systems, with the first dimen-
sion addressing quality, efficiency as well as acceptability
and the second dimension addressing equity [23]. Fur-
thermore, some studies have discussed conflicts and
trade-offs among different evaluation measures of the
health systems, including effectiveness, efficiency, and
equity [24]. Berwick et al. (2008) argued improving the
health care system requires simultaneous pursuit of
three aims: improving the experience of care, improving
the health of populations, and reducing per capita costs
of health care [25].
On the other hands, all health systems struggle with the
issue of meeting population health needs fairly under re-
source constraints [26]. Equity issues in resource alloca-
tion, especially in rationing the scarce drugs should
reduce health inequalities by adopting some policies, par-
ticularly the ones made to minimize or mitigate the effects
of the unequal distribution of resources affecting individ-
uals’ health status [27]. But the issue raised here goes be-
yond equity. The ethical aspects of such decisions has
been discussed in the accountability for reasonableness
framework (A4R) of Norman Daniels [26]. Theoretically,
the allocation problems pose formidable challenges to in-
dividuals who have to decide on the allocation of health
care resources at the times of scarcity [28, 29]. A key rec-
ommendation for meeting the A4R is that establishing a
fair process for priority setting is easier than agreeing on
principles [26]. Norman Daniels (1982) examined the eth-
ical presuppositions and implications of three accounts of
equitable access, a “use- (or use-per-need)” based account,
a “process” variable account, and “market” account [30]
with an ethical balancing.
More recently, academics have suggested a number of
factors as the ones probably associated with need-based
resource allocation to direct such decision processes. As
McIntyre and Anselmi (2012) stated, the most prevalent
indicators are demographical make-up, socio-economic
conditions, ill-health levels as well as population size
[16]. Obviously, in the absence of any gold standard
measure for a population’s health care need, the selec-
tion of valid, dependable, and accountable indicators (or
proxies) of health care is of great importance [21, 31].
Needless to note, when rationing decisions are made,
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careful weighing of the indicators is of paramount im-
portance to make sure that the indicators are not “ir-
rational” or “ethically objectionable as when they reflect
discriminatory attitudes” [20].
ANP and fuzzy ANP
Since the 1970s when Saaty proposed the Analytic Hier-
archy Process (AHP), its application has become prevalent
in the Multiple Criteria Decision-Making (MCDM) envir-
onment to address sophisticated decision-making prob-
lems [32, 33]. ANP, a generalized form of AHP, can be
applied as an efficient tool in the cases where the interac-
tions among the elements lead to the formation of a net-
work structure being beneficial under different real-world
conditions [34]. ANP approach is widely used for
prioritization, performance evaluation, and other contexts
[35, 36], and it can detect feedback and interdependent as-
sociations among and between the components [37].
Although ANP aims at capturing the expert’s know-
ledge, its traditional version failed to consider the human
thinking style, and, consequently, a fuzzy ANP (FANP)
was proposed. The application of fuzzy theory in
decision-making problems has provided favorable prac-
tical results [38]. Given that interval judgments is usually
more convenient for the decision-makers than the fixed-
value judgments, the application of a fuzzy ANP is valid
even in the cases of unavailable information or costly de-
pendable information [39]. The difference between two
ANP methods lies in extracting the weights of the pair-
wise matrix; otherwise, they are the same. Several re-
searchers have utilized a fuzzy ANP-based method to
solve complicated decision-making scenarios [40–42].
Both of these methods have been applied in healthcare
settings [36].
ANP in pharmaceutical decision-making
On the one hand, decisions made in the pharmaceutical
sector can have a direct impact on the living conditions
and health of the community. On the other hand, im-
proving health standards can provide the grounds for
economic development [43]. The pharmaceutical sector
should consider a large number of factors, particularly in
resource allocation process, to ensure the equitable dis-
tribution of resources and, ultimately, an optimal use of
scarce resources [10]. Accordingly, the use of MCDM
methods is particularly critical for pharmaceutical
decision-makers to support their decisions. ANP can be
defined as a multi-criteria theory, which enables the
decision-makers to structure a decision in the greatest
conceivable general manner. The representation of any
decision problem with no concern about what comes
first or next is possible using a network structure when
the sources, cycles, and sinks are addressed [44].
Applying ANP as MCDM can provide a more data-
driven and transparent decision process while taking in-
tangible aspects and decision-makers’ preferences into
account [44]. Furthermore, some recent studies have
suggested that ANP can be used as a part of a bench-
marking effort in selecting the best practice solution
[45]. Feibert et al. (2016) applied ANP to evaluate
pharmaceutical distribution solutions based on a set of
decision criteria specified to a healthcare logistics con-
text [36]. A managerial decision model was proposed by
Machado et al. (2014) and considered a Portuguese
pharmaceutical supply chain using ANP.
A thorough review of resource allocation in Iran’s
pharmaceutical system reveals the lack of suitable alloca-
tion/distribution indicators; therefore, the detection of
the relevant indicators would go a long way toward an
adequate allocation of scarce pharmaceutical resources.
To fill this gap, some further studies to evaluate the allo-
cation process of scarce drugs and to determine the rele-
vant indicators seems to be of greater urgency. The
present study aimed to identify and prioritize the alloca-
tion indicators using an ANP model to assist policy-
makers in distributing scarce drugs among different
provinces. The results of this study would contribute the
existing literature to reduce the impact of drug shortages
such as irreparable damage and premature death.
The contribution of this study lies in its potential to
provide a deeper understanding of the factors to be con-
sidered by policymakers in order to decrease the nega-
tive impact of misdistribution/misallocation of scarce
drugs through developing a conceptual model in accord-
ance with ANP. The study also extends the existing lit-
erature on health-care resource allocation through
determining the critical indicators for managing short-
ages in Iran based on the need-based resource allocation
concept.
Methodology
Three consecutive steps were taken to conduct the
present study. The methodology of this study is summa-
rized in Fig. 1.
First, to choice the allocation indicators, three phases
were conducted: The first was literature review to find
what indicators employed in the priority setting decision
context in health systems around the world. Then, in the
second phase, the indicators scrutinized by fifty aca-
demics and executives who were specialists in pharma-
ceutical resource allocation and distribution (including
the vice chancellors of food and drug in universities of
medical sciences along with other specialists of the field).
Finally, in third phase, a structured process was per-
formed based on the Delphi technique requirements to
finalize the indicators.
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Furthermore, according to the expert consultation
meetings, the indicators affecting the distribution of
scarce drugs among different provinces in Iran are not
completely separated and are interdependent as such
the multi-criterion techniques such as ANP to consider
interactions at the time of weighting is more conveni-
ent. Afterwards, the construction of ANP model was
developed according to both review of previous studies
and brainstorming decision-makers’ opinions. To run
the pairwise comparisons between clusters/elements of
ANP model, a questionnaire was developed and sub-
mitted to some experts. The phase was completed by
14 respondents, which 6 were academics and have
pharmaceutical policy making experience, 4 were ex-
ecutive members who worked in Iran FDA particularly
in time of crisis and shortages and 4 were specialists in
pharmaceutical resource allocation. The questions were
measured based on a nine-point scale, in which 1 repre-
sented equal significance and 9 indicated extra signifi-
cance of one element compared to another one. Finally,
the results were analyzed using the Super Decisions
software version 2.2.
In this paper, we ranked allocation indicators for drugs
in shortage using the fuzzy ANP technique. A variety of
fuzzy ANP methods have been introduced by different
researchers. In the present study, the extent analysis
method was used [46]. The steps involved in fuzzy ANP
are listed below [47]:
Step 1. Establishment of the model and problem
The main goal is divided into sub-goals, criteria/sub-cri-
teria and alternatives. Goal can be defined as what is
supposed to be obtained. While a set of parameters on
which decision depends is called criteria, alternatives
represent the elements according to which decision-
making should be performed.
Step 2: establishment of a fuzzy pairwise comparison
matrix (independent as well as interdependent) and
Defuzzification
Criteria and alternatives are also defined as a scale based
on the qualitative scale of significance proposed by Saaty
[34] and are subsequently converted into the quantita-
tive scale ranging from 1 to 9. Several forms of fuzzy
numbers are available, although Triangular Fuzzy Num-
bers (TFN) and trapezoidal fuzzy numbers have the
highest popularity [48]. Different trapezoidal/triangular
fuzzy numbers could be classified in order through the
portrayal of their curves in a fuzzy multiple-criteria
decision-making problem. Unless its order can be
ranked by its own figures, other approaches could be ap-
plied alternatively.
Fig. 1 Methodology
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Pairwise comparison was run after scaling. This means
that the corresponding significance of component i rela-
tive to component j with regard to the parent compo-
nent in the hierarchy is identified and allocated to the
position (i. j) of the pairwise comparison matrix [35].
The priorities among clusters, within cluster elements,
and between various cluster elements were established
based on pairwise comparisons as well as judgments.
The local priority vectors (Eigenvectors) obtained from
comparison matrix resulted in unweighted super-matrix
when obtaining global priorities in a system with inter-
dependent impacts. Then eigenvectors were entered into
the suitable columns of a matrix according to the impact
flow from a component to another component, i.e. a
supermatrix. The supermatrix exhibits similarities to
Markov chain process [49]. There are different available
defuzzification methods, out of which Liou and Wang’s
(1992) method was used in this paper, taken from the
study of Wu et al. [49].
Step 3: determination the eigenvectors and Supermatrix
formation
The calculation of the corresponding significance is per-
formed using eigenvalues along with eigenvector of the
comparison matrix.
Given the usual interdependencies of the clusters
across a network, the columns of a supermatrix typically
contain values larger than one. The transformation of
the supermatrix is first necessary to specify its stochastic
properties, indicating that each column of the matrix en-
hance the unity. The approach recommended by Saaty
(1996) includes determining the corresponding signifi-
cance of the clusters in the supermatrix, in which the
column cluster (block) represents the controlling com-
ponent. This means that the comparison of the row
components having blocks with non-zero entries in the
same column block is performed based on their impacts
on the components of the same column block [49]. An
eigenvector is to be acquired for each column block
using the pairwise comparison matrix of the row compo-
nents with regard to the column component. For each
column block, the first entry of the corresponding eigen-
vector is multiplied by all the elements in the first block
of the same column. The same process is carried out for
the next column blocks, according to which the blocks
in each column of the supermatrix are weighed, result-
ing in a weighted supermatrix with stochastic features.
Increasing a matrix power would better reflect the long-
term corresponding impacts of the elements on each
other. To obtain the convergence of the significance
weights, the weighted supermatrix is raised by the power
2 k + 1, where k indicates a randomly large number, and
the new matrix is known as the limit supermatrix [50].
The same procedure is performed for each level of the
hierarchy as long as the decision-making process is com-
pleted. In the case of similar entries for each column,
the limit matrix is achieved and the matrix multiplica-
tion process continues no further. The normalization of
the blocks in this supermatrix results in eventual prior-
ities for all the elements of the matrix.
Step 4: evaluation of the decision
If the supermatrix obtained in the previous step covers
the entire network, it is possible to find the priority of
weights for the alternatives in the columns of the nor-
malized supermatrix. On the other hand, when a super-
matrix just includes interrelated components, further
calculation is needed to achieve the total priorities for
the alternatives. The alternative with the highest total
priority will be selected.
It is of great importance to make consistent compari-
sons to ensure that judgment reliability is considered.
To this end, Consistency Index (CI) and Consistency Ra-
tio (CR) are proposed. CR and CI represent the
consistency ratio and the consistency index of the ran-
dom reciprocal matrix produced by a quantitative 9-
point scale [32]. If CR < 0.1, it is accepted; otherwise, the
pairwise comparison requires revision.
Results
After reviewing the methods and effective indicators of
scarce resources allocation in the world, about 20 indica-
tors was detected, which based on availability of data in
Iran, 16 indicators entered to the next step. Then, in the
second phase, the indicators scrutinized by experts and
just 3 indicators were rejected and 13 indicators entered
to the Delphi phase. Finally, the Delphi technique was
performed and 8 indicators contained the burden of en-
demic, special, rare and incurable and traumatic dis-
eases, total population, the population of non-resident
patients, total bed occupancy rate, number of prescrip-
tions and the number of general practitioner (GPs) and
specialist were approved. Our finding showed that eight
of the common measures/indicators of resource alloca-
tion were rated face valid for measuring need and cur-
rently used in need-based resource allocation formula in
other countries. (for further information, see Zarei
(2019)) [51]. According to Berwick (2008) [25] and
Wenzel (2008) [24], clinical improvement (effectiveness),
population health improvement (equity and access), and
reducing cost (economic & resources aspects -efficiency)
are the paradigms for the allocation of limited resources
or explicit priority settings. The results of this section
are presented in Table 1.
Next, a network of indicators affecting scarce drug al-
location was developed and prioritized using ANP
method. The computational procedure of ANP method
is summarized below:
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Efficiency The ability to avoid wasting resources in doing something or in
producing a desired result. In a more general sense, it is not




Population size in a geographical area.
Non-resident
patient









Number of general practitioner and specialists




The number of beds effectively occupied (bed-
days) of each province.
Number of
prescriptions
The total number of prescriptions filled annually in
each province.
Effectiveness What extend a goal could be reached. If a goal cannot be
reached, any resource input is wasted.
The measure of effectiveness can be multidimensional.
Burden of
diseases
Burden of endemic diseases: The burden of the
diseases that always present in a certain population
or region.
Burden of special, rare and incurable diseases:
In Iran, dialysis patients, thalassemia, hemophilia,
cancer, MS, kidney transplant, diabetes and E. B are
covered by this group.
Burden of traumatic diseases: Any injury that
goes beyond the body’s resilience and leads to
lesions in the body is called trauma, which includes
accidents, events, falls from heights, and even the
psychological and chemical damage.
Fig. 2 The ANP model
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Step 1. Establishment of the model and problem
The ANP model (Fig. 2) shows the inner and outer de-
pendencies. The model is supposed to determine the
most important indicators of optimal allocation/distribu-
tion of drugs in shortage.
As presented in Fig. 2, a unidirectional arrow shows
that one cluster/cluster element has impacts on the
other ones (outer influence or inner influence). This
arrow goes from the “Efficiency” cluster toward the
“Equity and access” cluster, indicating that the value of
the “Equity and access” cluster depends on the judg-
ments made in the “Efficiency” cluster (see Appendix
Table S1).
A 45-item questionnaire was developed with regard to
the relationship determined by ANP model and submit-
ted to 14 experts to elicit the most important indicators
for the allocation/distribution of drugs in the short sup-
ply (The questionnaire are presented in Appendix 2). A
response rate of 89% was obtained. Pairwise compari-
sons were performed using a nine-point priority scale
with 1 showing identical significance and 9 representing
the extreme significance of an element compared to the
other’s.
Step 2: establishment of the fuzzy pair-wise comparison
matrix (independent and interdependent) along with
Defuzzification
Although different forms of fuzzy numbers could be
used, we applied triangular fuzzy numbers (TFN) in this
study. TFN is simply represented as (L, M, U), where the
parameters L, M, and U indicate the smallest probable
value, the most promising value, and the biggest prob-
able value in describing a fuzzy event, respectively. TFN
can be applied to indicate the fuzzy opinions as well as
the expert consensus. In this paper, we used the proced-
ure suggested in Wu’s et al. (2008) [49] study to define
TFN. In Table 2, the fuzzy aggregate pair-wise compari-
son of the decision paradigms is presented with regard
to the main goal. After defuzzification, the fuzzy weight
of paradigms was converted into a certain weight and
was the normalized.
Afterwards, these steps were repeated for different
sub-criteria with respect to the relevant paradigms, and
there was a pair-wise comparison of the internal rela-
tionships between each cluster/paradigm and sub-
criteria (elements).
Step 3: determining the eigenvectors and Supermatrix
formation
After measuring the preferences using the Improved
Fuzzy AHP (IFAHP) method, the final weights of the
criteria and sub-criteria were achieved (see Appendix
Table S2).
The Appendix Table S3 shows the supermatrix along
with corresponsing vectors and matrices, which were
previously achieved. Since the supermatrix consists of
the interactions between clusters, inner dependence is
present among criteria and witnin sub-criteria, and the
columns contained no 1. The transformation of a
weighted supermatrix was first performed to make it
stochastic (see Appendix Table S4). Following the inser-
sion of the normalized values into the supermatrix and
the completeion of the column stochastic, the superma-
trix power was enhanced to an acceptable level so that
convergence was observed. Convergence was reached for
the current supermatrix, and a unique eigenvector was
also obtained. The Appendix Table S5 indicates the final
limit matrix, which is column-stochastic and reflects the
final eigenvector. Finally, the final and normalized
weight as well as the priority of each criterion/element
was obtained (Table 3).
The priority synthesis with respect to the goal was as
follows: Equity and Access (0.459), Efficiency (0.37), and
Effectiveness (0.171).
According to the model results, the most important
indicators are ‘number of prescriptions’ and ‘total bed
occupancy rate’ if the equity paradigm is considered and
‘total population’ if the efficacy paradigm is considered.
According to the results of the limit matrix, ‘number of
prescriptions’ (W = 0.262) and ‘burden of endemic dis-
eases’ (W = 0.053) were the most and the least important
indicators for allocation of scarce drugs, respectively.
Furthermore, total population is introduced as the sec-
ond most important indicator, followed by ‘total bed oc-
cupancy rate’.
Moreover, “burden of special, rare, and incurable dis-
eases” (W = 0.077) in the cluster “Effectiveness” had the
highest weight and was the main indicator in the cluster.
Step 4: evaluation of the decision
All the clusters underwent the consistency analysis, re-
sulted in a consistency ratio < 0.1, which always pre-
sented and reflected consistent results.
Table 2 Fuzzy Aggregate Pair-wise Comparison and weight of the paradigms
Criteria/Paradigms Efficiency Equity & Access Effectiveness Normal weight Certain weight
Efficiency (1,1,1) (0.38,0.449,0.551) (0.302,0.35,0.405) 0.166 0.168
Equity & Access (1.815,2.228,2.634) (1,1,1) (1.063,1.197,1.351) 0.424 0.428
Effectiveness (2.472,2.853,3.315) (0.74,0.835,0.941) (1,1,1) 0.409 0.413
CRm:0.021 consistency ratio (mean values); CRg:0.063 consistency ratio (geometric means of lower and upper bounds)
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Discussion
Health resources allocation processes differ across coun-
tries and fundamentally depend on how the delivery of
healthcare and related services is organized. In Iran, a
limited ration of pharmaceutical products was distrib-
uted by IFDA in the case of scarcity; indicating that
IFDA decides how best to ration allocations. This study
aimed to identify and prioritize scarce drug allocation in-
dicators to assist Iranian healthcare policymakers in
making more efficient, effective, and equitable decisions.
According to the results of previous studies and the
review of the relevant literature, eight need-based indica-
tors of scarce drug allocation were detected and classi-
fied into three clusters, namely efficiency, equity, and
effectiveness. This classification had been previously
used by some other researchers [24, 52–54]. For in-
stance, Berwick et al. (2008) claimed the triple aim of
public healthcare systems are clinical improvement (ef-
fectiveness), population health improvement (equity and
access), and reducing cost (economic aspects -efficiency)
[25]. The results from ANP technique suggest that
“equity and access” is the most important paradigm for
the allocation of scarce drugs. This finding is consistent
with those of the other studies [27, 55–57]. Because
based on the current situation, when a drug is in short
supply in a province, it is possible that the neighboring
province, which does not need it, will be in abundance.
So, after sharing information, some provinces may feel
discriminated against. This highlights the importance of
the equity aspect.
In terms of access, the problems associated with sanc-
tions and the provision of Active Pharmaceutical Ingre-
dient (API) have always bothered our country, and drug
suppliers have always faced the problem of access, Iran
has been under in shortages since 2012 due to sanctions.
This is more even challengeable in the case of access to
medicine for incurable and rare disease. In the case of
burden of rare disease, due to their heavy social impacts,
participants have always been considered because of
their responsiveness to these patients and the specific
political burden that these patients can place on the
system.
In addition, “number of prescriptions” is the most im-
portant indicator in this cluster. In other words, “num-
ber of prescriptions” is the most acceptable indicator
among all the studied indicators, implying the signifi-
cance of including the needs in the supply side. In the
absence of adequate direct need-based data, it would be
difficult to distinguish the effects of true needs on
utilization from the effects of supply and demand.
Gaminde (1999) [58] argues that the effects of supply
side (by the prescribers) in pharmaceutical sector is
greater than those of the demand side (by the con-
sumers). Accordingly, the number of prescriptions as a
proxy of need determined by the prescribers plays a crit-
ical role in the allocation of scarce drugs. This finding is
also in a similar vein with the findings of the previous
studies [59].
The first indicator of need is population size in a geo-
graphical area [13] as such an increase in the covered
population is expected to enhance the pharmaceutical
resource use due to the increased utilization of health
services [14]. Like the findings in [13, 21, 31, 60], “total
population” in this study was the most important indica-
tor in the efficiency cluster. In addition, “total bed occu-
pancy rate” as another indicator in the equity cluster
was also listed as the first three important indicators.
This finding is also similar to the findings in [57, 59].
Moreover, the results of ANP technique showed that
“burden of special, rare, and incurable diseases” was the
most important indicator in the effectiveness cluster,
highlighting the role and significance of disease burden
in the designation of overall health status for different
groups or geographic areas. In the case of “burden of
Table 3 The final weight and priority
Clusters/
Paradigms










Efficiencya Total population 0.694 2 0.211 0.370 2
Non-resident patient 0.306 5 0.075
Equity and
Accessb
Number of general practitioner
and specialists
0.172 7 0.046 0.459 1
Total bed occupancy rate 0.383 3 0.190
Number of prescription 0.445 1 0.262
Effectivenessc Burden of endemic diseases 0.341 8 0.053 0.171 3
Burden of special, rare and
incurable diseases
0.375 4 0.077
Burden of special, rare and
incurable diseases
0.284 6 0.068
aCRm: 0.011 CRg: 0.056, b CRm: 0.014 CRg: 0.035, cCRm: 0.028 CRg: 0.074
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special, rare, and incurable diseases”, due to their heavy
social impacts, participants have always been considered
because of their responsiveness to these patients and the
specific political burden that these patients can place on
the system.
If a need is defined in terms of the burden of disease,
morbidity, and mortality, then the lower income groups,
who are presumably sicker and in greatest need, would
have greater need for health services [61]. This indicator
had been previously used by many other countries in re-
source allocation formula in the case of scarcity [16, 27,
61, 62]. The burden diseases are important indicators
because the allocation of medicines to provinces that do
not need it at the moment is obvious, which is result of
historical distribution and ad hoc resource allocation
decision-making.
According to the findings of the present study, ‘non-
resident patients’ is another indicator of the efficiency
cluster, which should be considered in scarce resource
allocation. This finding is already confirmed by some
other studies [60].
For MCDM, to gain wider use as a decision support
tool, decision makers must choose techniques based on
their fit to the decision context, and cognitive and time
demands in collecting and analyzing their results [63].
Heretofore, despite the efforts of the Iran FDA, generally
the decisions are based on emotional intelligence and
there is no specifically conceptual framework or indica-
tors to priority settings. So, although the weight of indi-
cators has less applicability in real life, it presenting list
of indicators and their priorities which should be consid-
ered in allocation decisions. Yet, there may always be
disagreement about the importance of criteria when set-
ting priorities. For this reason, ethicists have stressed the
importance of fair processes, which allow key stake-
holders to agree on what is legitimate and fair [26, 64].
Therefore, the accountability for reasonableness frame-
work of Norman Daniels could further feed the alloca-
tion model proposed by this study [26]. Since efficiency,
equity and effectiveness are considerations that some-
times conflict with each other, decision makers need to
weigh them against each other and make trade-offs.
Lastly, procedures for revising decisions in the light of
reasonable challenges to them should be put in place.
Limitations
There are some limitations that should be taken into ac-
count when interpreting the results of this study. Re-
garding the weighting technique choice, the fuzzy ANP
is interesting from a methodological point of view but
rather challenging from a pragmatic decision-making
point of view (complex mathematics hard to put in ac-
tion), and from an ethical point of view. ANP is an indir-
ect method, which uses the model to prioritize and rank.
Balancing the paradigms is an ethical exercise, value-
laden, and which varies according to the worldview of
each individual.
Conclusions
In general, the ability to overcome inefficient resource
allocation patterns caused by both oversupply and un-
dersupply derived from historic resource allocation
might be highly limited in the absence of the need indi-
cators. The more sensible the indicators of population
needs are, the more equitable distribution will be. Never-
theless, no golden rule is found regarding what weights
to be. Identifying the weights of the determined indica-
tors would necessarily be a policy decision requiring de-
tailed considerations and discussions. Although resource
allocation indicators do not reveal much difference for
most provinces, their significance varies from province
to province.
The development of the resource distribution models
has is of great advantage for providing a structure for
decision makers to set priorities in more deliberant and
transparent process and also improve quality of alloca-
tion decisions through minimizing tasteful behaviors.
The ANP resource allocation/distribution model devel-
oped in this study structured the scarce drug allocation
problem, critical paradigms, and rationing indicators.
The proposed model was superior to the previous alloca-
tion models in terms of including and quantifying inter-
dependencies among system components. Furthermore,
the application of a fuzzy theory would be effective in
dealing with the intrinsic uncertainty and lack of preci-
sion posed by mapping a decision-maker’s perceptions
of exact numbers. FANP approach provides IFDA with
more dependable and realistic allocation scores. Both
the indicator scores and the weights of the resource allo-
cation paradigms are provided by the model. To sum up,
this model is suggested to be used by decision makers in
the allocation of drugs in short supply more equitably,
efficiently, and effectively.
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